Join to View Full Profile
6610 Rockledge DrRm 6616Bethesda, MD 20817
Phone+1 301-435-4411
Fax+1 301-402-2571
Dr. Bianchine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- 26+ years service in DHHS. Internal Medicine, Allergy & Immunology, Clinical Trial Design & Analysis, Strategic Regulatory Affairs, Medical Writing; Pharmacovigelance, NIAID Contracting Officer’s Technical Representative for the Immune Tolerance Network Data Coordinating Centers, and Administrative Coordinator for five DAIT, NIAID Data and Safety Monitoring Boards and two Data Monitoring Committees. Level III (Senior/Expert) NIAID Contracting Officer’s Technical Representative (FAC-COR) Certification: June 07, 2012 to Present for federal contracts up to or exceeding $25 Million. Medical Monitor for selected clinical trials sposored by DAIT, NIAID.
Recent Ref: Am J Transplant. 2016 Feb;16(2):509-17. doi: 10.1111/ajt.13458. Epub 2015 Oct 3.
Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. Brennan DC, Kopetskie HA, Sayre PH, Alejandro R, Cagliero E, Shapiro AM, Goldstein JS, DesMarais MR, Booher S, Bianchine PJ.
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1990 - 1995
Rhode Island Hospital/Brown University HealthResidency, Internal Medicine, 1987 - 1990
Brown University School of MedicineMD, Medicine, 1985 - 1987
The Warren Alpert Medical School of Brown UniversityClass of 1987- Dartmouth Medical SchoolMed School Yrs 1 and 2, Medicine, 1983 - 1985
- Massachusetts Institute of TechnologyB.S., Biology, 1979 - 1983
Certifications & Licensure
MD State Medical License 1990 - 2020
Clinical Trials
Publications & Presentations
PubMed
- 113 citationsLong‐Term Follow‐Up of the Edmonton Protocol of Islet Transplantation in the United StatesDaniel C. Brennan, H. Kopetskie, Peter H. Sayre, Rodolfo Alejandro, Enrico Cagliero
American Journal of Transplantation. 2016-02-01 - 251 citationsRapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell FunctionS. Alice Long, Mary Rieck, Srinath Sanda, Jennifer B. Bollyky, Peter L. Samuels
Diabetes. 2012-09-01 - 153 citationsTreatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.Kevan C. Herold, Stephen E. Gitelman, Carla J. Greenbaum, Jennifer M. Puck, William Hagopian
Clinical Immunology. 2009-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
